微波消融治疗内科无法手术的I期非小细胞肺癌的长期结果
本多中心回顾性研究纳入2011年2月至2016年3月105例经组织学证实为临床I期非小细胞肺癌且内科无法手术的患者,行CT引导下微波消融,中位随访54.8个月,中位总生存期64.2个月,1、3、5年总生存率分别为99%、75.6%、54.1%,结论认为微波消融是安全、有效且可能根治的治疗选择。
要点
- 中位随访54.8个月,中位总生存期64.2个月,1、3、5年总生存率分别为99%、75.6%、54.1%。
- IB期病变较IA期无病生存期(22.3个月 vs 未定义,HR 11.5)和总生存期(37.3个月 vs 89.8个月,HR 8.64)显著更短。
- 全部患者手术技术成功且耐受良好,多数微波消融并发症为轻至中度。
核心结论
- 微波消融是内科无法手术的I期非小细胞肺癌患者安全、有效且可能根治的治疗方法。
研究设计与样本
- 多中心回顾性研究,纳入2011年2月至2016年3月经组织学证实的临床I期非小细胞肺癌患者105例(105个病灶),行CT引导下微波消融,主要终点为总生存期。
诊断标准与关键数值
- 中位随访54.8个月,中位无病生存期36.0个月,1、3、5年无病生存率分别为89.5%、49.4%、42.7%。
- 中位肿瘤特异性生存期89.8个月,中位总生存期64.2个月。
- 1、3、5年总生存率分别为99%、75.6%、54.1%,肿瘤特异性生存率分别为99%、78.9%、60.9%。
- IB期病变较IA期无病生存期显著更短(22.3个月 vs 未定义,HR 11.5,95%CI 5.85-22.40)。
- IB期病变较IA期总生存期显著更短(37.3个月 vs 89.8个月,HR 8.64,95%CI 4.49-16.60)。
临床应用与阅片要点
- 原文结论认为微波消融是内科无法手术的I期非小细胞肺癌患者安全、有效且可能根治的治疗方法。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: In the present study, we aim to show the results of microwave ablation (MWA) for medically inoperable stage I non-small cell lung cancers (NSCLCs) with long-term follow-up.
METHODS: From Feb 2011 to Mar 2016, patients with histologically proven clinical stage I NSCLC were treated with CT-guided MWA and retrospectively analyzed. The primary end point was overall survival (OS). Secondary end points included disease-free survival (DFS), cancer-specific survival (CSS), and complications.
RESULTS: A total of 105 patients with 105 lesions underwent MWA. The mean age was 70.7 years (range: 40-86 years), and the mean diameter of all lesions was 2.40 cm (range: 0.9-4.0 cm). Adenocarcinoma was the most common histological type (77, 73.3%), followed by squamous cell carcinomas (21, 20%) and undefined NSCLC (7, 6.7%). With a median follow-up of 54.8 months, the median DFS was 36.0 months, and 1-, 3-, and 5-year DFS rates were 89.5%, 49.4%, and 42.7%, respectively. The median CSS and OS were 89.8 and 64.2 months, respectively. The OS rate was 99% at 1 year, 75.6% at 3 years, and 54.1% at 5 years, while the CSS rates were 99%, 78.9%, and 60.9%, respectively. Patients with stage IB lesions had significant shorter DFS (22.3 months vs. undefined, HR: 11.5, 95%CI: 5.85-22.40) and OS (37.3 vs. 89.8 months, HR: 8.64, 95% CI: 4.49-16.60) than IA disease.
CONCLUSION: MWA is a safe, effective, and potentially curative therapy for medically inoperable stage I NSCLC patients.
KEY POINTS: • In this multicenter retrospective study which included 105 patients, we found the median overall survival (OS) was 64.2 months. The OS rate was 99% at 1 year, 75.6% at 3 years, and 54.1% at 5 years. • Procedures were technically successful and well tolerated in all patients. Most MWA complications were mild or moderate.
引用
- Ni, Huang, Yang, et al. Microwave ablation treatment for medically inoperable stage I non-small cell lung cancers: long-term results. Eur Radiol. 2022. PMID: 35226157. doi:10.1007/s00330-022-08615-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。